Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Department of Geriatrics, Hematology & Oncology Ward, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180 Guangdong, China.
Pharmacol Res. 2020 Mar;153:104659. doi: 10.1016/j.phrs.2020.104659. Epub 2020 Jan 23.
Regulatory T cells (Tregs) modulate ongoing immune responses to prevent autoimmunity in healthy bodies and inhibit effective anti-tumor immunity responses in tumor patients, leading to tumor progression. The function of Tregs in tumor immunity suggests that elimination of Tregs in the host may enhance the anti-tumor immune response. Despite the success of strategies for depleting Tregs in tumor-bearing patients, the overall clinical efficacy is limited and accompanied by undesirable side effects. The present review describes the diverse anti-tumor roles and differentiation mechanisms of heterogeneous Tregs and proposes methods for modulating them in the tumor microenvironment. This information is critical for improving clinical outcomes and preventing adverse effects in cancer patients receiving immunotherapy targeting Tregs.
调节性 T 细胞(Tregs)调节持续的免疫反应,以防止健康体内的自身免疫,并抑制肿瘤患者中有效的抗肿瘤免疫反应,从而导致肿瘤进展。Tregs 在肿瘤免疫中的功能表明,消除宿主中的 Tregs 可能会增强抗肿瘤免疫反应。尽管在肿瘤患者中耗尽 Tregs 的策略取得了成功,但总体临床疗效有限,并伴有不良副作用。本综述描述了异质性 Tregs 的多种抗肿瘤作用和分化机制,并提出了在肿瘤微环境中调节它们的方法。这些信息对于改善接受针对 Tregs 的免疫疗法的癌症患者的临床结果和预防不良反应至关重要。